雷贝拉唑钠/甲硝唑/阿莫西林(Rabeprazole Sodium/Metronidazole/Amoxicillin) - 药物靶点：Proton pump_在研适应症：胃炎，十二指肠溃疡，幽门螺杆菌感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Clofezone、Rabeprazole、Rabeprazole Sodium/Amoxicillin Hydrate/Metronidazole

+ [4]

靶点

Proton pump

作用方式

抑制剂

作用机制

质子泵抑制剂、细胞壁抑制剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

权益机构

Woodward Pharma Services LLC

Eisai Co., Ltd.

最高研发阶段批准上市

首次获批日期

日本 (2013-08-15),

十二指肠溃疡幽门螺杆菌感染免疫性血小板减少症+ [1]

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C16H21N3O6S

InChIKeyAIPFZZHNBUVELL-YWUHCJSESA-N

CAS号61336-70-7

查看全部结构式(3)

关联

50

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床试验

ACTRN12624000878572

/ Completed临床1期

A Phase 1, Fixed Sequence, Open-Label Study to Evaluate the Effect of Multiple Doses of Rabeprazole on the Pharmacokinetics of a Single Dose of Radiprodil in Healthy Adult Participants

开始日期2024-08-26

申办/合作机构

GRIN Therapeutics, Inc.

[+1]

NCT04923113

/ CompletedN/AIIT

Comparison of Different Helicobacter Pylori Detection Methods in Patients With Chronic Atrophic Gastritis

As we know，Helicobacter pylori is closely related to many gastrointestinal diseases such as chronic gastritis, peptic ulcer disease,gastric carcinoma and gastric mucosa-associated lymphoid tissue lymphoma，as well as extra-digestive diseases such as urticaria and chronic obstructive pulmonary diseases and so on.The diagnosis of H. pylori infection is based on invasive methods requiring endoscopy and biopsy(e.g. histology, culture, rapid urease test, PCR) or on non-invasive methods (e.g. serology, 13C urea breath test, stool antigen test).Histology has the highest specificity among the others,and also allows us to determine the underlying disease and perform antibiotic sensitivity testing.Serological tests are widely available and more appropriate for epidemiological studies, their main weakness for clinical use is low specificity.The 13C urea breath test is the most accurate method in patients irrespective of age.Stool antigen testing,as a promising method, is easy to perform, and its accuracy may be improved by the use of monoclonal antibodies recently proposed for capturing H. pylori antigen in stool specimen.Sensitivity and specificity, usefulness,and limitation of tests should be considered for selection of detection methods of H. pylori. Our objective is to review the current methods that are used for the detection of H. pylori infection among patients with chronic atrophic gastritis.Except that,patients with Hp positive will be further treated with 10-day minocycline-based quadruple therapy,to observe the efficacy and safety of minocycline-based regimen for H.pylori eradication as a first-line therapy.

开始日期2021-06-28

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

NCT04565574

/ Completed临床1期

An Open-Label, Single-Dose Study to Assess the Effect of Food Intake and Drug-Drug Interactions of E7090 When Co-administered With Rabeprazole (Gastric Acid-Reducing Agent), or Rifampin (Strong CYP3A Inducer) in Healthy Subjects

This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A [CYP3A] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.

开始日期2020-10-16

申办/合作机构

Eisai Co., Ltd.

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的临床结果

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的转化医学

登录后查看更多信息

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的专利（医药）

登录后查看更多信息

1,204

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的文献（医药）

2026-06-01·BIOORGANIC CHEMISTRY

Rapid discovery of repurposed drugs targeting SARS-CoV-2 spike HR1 by DNA-encoded library screening

Article

作者: Wang, Fei ; Yang, Guang ; Yan, Lei ; Liu, Lili ; Xue, Qingao ; Wang, Fulian ; Liang, Ze ; Zhang, Yi

The membrane fusion process mediated by the SARS-CoV-2 spike protein is a key therapeutic target. Its heptad repeat 1 (HR1) domain forms a conserved trimeric groove critical for forming the fusion-competent six-helix bundle with HR2. We used DNA-encoded library screening to identify small molecules binding HR1. Hits including Rabeprazole-related compound E (Rab RCE), Omeprazole, Alvimopan, and Olmesartan were characterized. Biophysical assays confirmed binding, while computational simulations revealed distinct interaction modes, with Alvimopan showing high predicted affinity. Cell-cell fusion assays demonstrated potent inhibitory activity for Olmesartan and Rab RCE. Notably, Rabeprazole and Rab RCE showed partial antiviral activity against SARS-CoV-2 variants and HCoV-OC43, rescuing virus-induced apoptosis. Mechanistically, Rabeprazole competitively occupies the HR2-binding groove on HR1, blocking fusion. Our findings identify HR1-targeting molecules like Rabeprazole as promising leads for broad-spectrum coronaviral fusion inhibitors.

2026-03-04·BIOCHEMICAL JOURNAL

Post-translational modifications of triosephosphate isomerase reveal metabolic vulnerabilities in T-ALL: effect of combining dichloroacetic acid and the PPI rabeprazole

Article

作者: Gómez-Manzo, Saúl ; Martínez-Pérez, Yoalli ; De la Mora-De la Mora, Ignacio ; Hernández-Hernandez, José Manuel ; Olaya-Vargas, Alberto ; León-Avila, Gloria ; Enríquez-Flores, Sergio ; Hernández-Alcántara, Gloria ; Flores-Braulio, C. Yusiel ; González-Rubio, Fernando ; López-Herrera, Gabriela ; García-Torres, Itzhel ; Flores-López, Luis A.

Abstract:

Acute lymphoblastic leukemia, particularly the T-cell subtype, remains associated with poor outcomes in relapsed and adult patients, highlighting the need for novel therapeutic strategies. Metabolic reprogramming, especially glycolytic dependence, represents a promising target. Triosephosphate isomerase (TPI), a key glycolytic enzyme, undergoes cancer-associated post-translational modifications (PTMs), including deamidation and phosphorylation. Here, we evaluated the potential of proton pump inhibitors (PPIs), particularly rabeprazole (Rbz), to selectively target PTM-bearing TPI isoforms in Jurkat cell model. Recombinant TPI variants engineered to mimic PTMs exhibited increased reactivity toward thiol-modifying agents and higher predicted binding affinities for PPI compared with wild-type TPI. Consistent with these properties, biochemical assays demonstrated preferential inhibition of the deamidation- and phosphorylation-mimicking proteins, with Rbz significantly reducing their enzymatic activity. Native gel electrophoresis of Jurkat cells protein extracts revealed drug-induced accumulation of acidic TPI isoforms, whereas normal T lymphocytes predominantly retained unmodified TPI. Rbz selectively impaired intracellular TPI activity and viability in Jurkat cells, effects enhanced by dichloroacetate (DCA) co-treatment. This inhibition correlated with marked accumulation of methylglyoxal and advanced glycation end products. Finally, combined DCA–Rbz treatment induced extensive apoptotic death in Jurkat cells while sparing normal lymphocytes. These findings identify PTM-bearing TPI isoforms as selective metabolic vulnerabilities in Jurkat cells and support the potential repurposing of thiol-modifying agents, particularly, Rbz, as targeted antileukemic strategies.

2026-03-01·Current drug discovery technologies

In silico Analysis to Search for an Alternative Inhibitor of Biofilm Production by Helicobacter pylori

Article

作者: Bhattacharya, Debasmita ; Nag, Moupriya ; Gupta, Avi ; Lahiri, Dibyajit ; Mitra, Debanjan ; Gupta, Jai

Introduction::

Antibiotic Resistance is a growing concern in the current world. Regarding this, Helicobacter pylori is known to be present in the digestive tracts of human beings. In some people, the infection leads to stomach cancer. With the increasing problem of Antibiotic resistance, reports show that drugs are no longer working with the same efficacy rate as they used to. The present work is a study of the two-component Acid-Response System (ArsRS) protein, one of the key pro-teins involved in biofilm formation by H. pylori.

Methods::

In this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with H. pylori. The molecular docking studies have been done with common drugs that are used for the treatment of the infection caused by H. pylori as Amoxicillin, Clarithromycin, Tetracycline, Levofloxacin, Metronidazole, Omeprazole, and Rabeprazole. Another aspect of the current study was to investigate the potential for national compounds such as Quercetin, α-mangostin, Phytol, Liquiri-tin, and D-mannitol as an alternative therapeutic agent. ADMET Analysis and toxicity assessment were done to check the pharmacokinetics of the bioactive compounds. An in silico investigation of the H. pylori protein revealed its stability and compactness.

Results::

A Higher number of intra-protein interactions increases the stability of H. pylori protein. Liquiritin emerged as an active molecule that can be used for inhibiting H. pylori biofilms. The FDA-approved drug Clarithromycin showed the highest binding energy among the synthetic group.

Discussions::

The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.

Conclusions::

Bioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.

6

项与雷贝拉唑钠/甲硝唑/阿莫西林相关的新闻（医药）

2025-06-02

·eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

上市批准

2025-03-29

·ETPharma

103 drug samples fail CDSCO quality test, popular brand Telma H flagged as spurious

New Delhi: During its monthly quality review, the drug regulatory body identified 103 drug samples as ‘Not of Standard Quality’ ( NSQ ) and flagged a sample of the popular brand Telma H as ‘spurious.’ Of the 103 drug samples that failed to meet the quality standards, 47 were identified by central drug laboratories, while the remaining 56 were identified by state drug laboratories in the country. The drug sample that has been labeled as “spurious” is Telma H (Telmisartan 40mg & Hydrochlorothiazide 12.5mg), a popular brand prescribed for high blood pressure patients. As per the Union Health Ministry note, the sample was picked from West Bengal. As per the February drug alert issued by the Central Drugs Standard Control Organisation (CDSCO), the sample was manufactured in 2022 and the reason for the drug test failure as notified in the alert suggests that the sample “does not conform to I.P.” (Indian Pharmacopoeia). The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 50 brands in the country, with a moving annual total (MAT) value of around ₹447 crore. Regarding the identified spurious drug sample, the Health Ministry, in its quality review announcement, stated that the sample is “made by an unauthorized manufacturer using a brand name owned by another company. The matter is under investigation and action.” CDSCO, in its drug quality alert, has remarked that the product is purported to be spurious; however, the same is subject to the outcome of the investigation. The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The 47 NSQ samples identified by the central laboratories include Rabeprazole Tablets manufactured by Martin & Brown BioSciences Pvt. Ltd.; Paracetamol & Diclofenac Sodium Tablets manufactured by I.G. PHARMA LTD.; and Telmisartan Tablets IP by Orison Pharma International, among 44 others. Whereas, the list from state laboratories comprises Calcium & Vitamin D3 Tablets manufactured by Affy Parenterals Vill.; Phenytoin Tablets by Jackson Laboratories; and Cloprostenol Injection by Monatt Biotech, including 53 others. According to CDSCO, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; if it is an imitation of, or a substitute for, another drug; if it resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among other provisions defined under Section 17-B of the Drugs and Cosmetics Act, 1940. Whereas drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Abhijeet Singh ,

2024-06-13

·Pharmaindustrial

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders. GERD, or gastro-oesophageal reflux disease, is a debilitating condition characterised by the reflux of stomach contents into the oesophagus, leading to troublesome symptoms and potential complications. With GERD often dubbed as chronic acid reflux, its prolonged presence not only impacts the quality of life but also poses risks of serious health complications, including stomach and esophageal cancer. “Rabeprazole sodium, a potent antisecretory compound, selectively inhibits gastric acid secretion by targeting the H+ and K+ ATPase at the surface of gastric parietal cells. It has demonstrated efficacy in treating gastric and duodenal ulcers, as well as GERD. Complementing rabeprazole, Levosulpiride, the levo-enantiomer of sulpiride, exhibits significant central antidopaminergic activity and antiemetic effects,” the company said in a statement. Its peripheral anti-dopaminergic action modulates the motor activity of the upper digestive tract, making it valuable in gastro-enterology, it claimed. “We are excited to introduce a solution for patients suffering from GERD and related gastrointestinal disorders. GERD diagnosis and treatment rely on symptom management and acid suppression therapies. Our Rabeprazole + Levosulpiride SR Capsules aim to offer an effective remedy, ease symptoms, enhance gastrointestinal function, and boost patients’ overall well-being. Levosulpiride offers rapid relief and better healing outcomes with fewer side effects, elevating the overall treatment experience,” Arushi Jain, Director, Akums Drugs & Pharmaceuticals Ltd. said in a statement. Each hard gelatin capsule contains Rabeprazole Sodium IP 40 mg (as enteric-coated form) and Levosulpiride 75 mg (as uncoated sustained-release form). The recommended dosage is one capsule once daily or as directed by a physician.

上市批准

100 项与雷贝拉唑钠/甲硝唑/阿莫西林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	雷贝拉唑钠/甲硝唑/阿莫西林	J01CR02	DB01129

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胃炎	日本	Eisai Co., Ltd.	2013-11-21
十二指肠溃疡	日本	Eisai Co., Ltd.	2013-08-15
幽门螺杆菌感染	日本	Eisai Co., Ltd.	2013-08-15
免疫性血小板减少症	日本	Eisai Co., Ltd.	2013-08-15
胃溃疡	日本	Eisai Co., Ltd.	2013-08-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	美国	Eisai, Inc.	2002-09-01
胃食管反流	临床3期	美国	Eisai, Inc.	2002-09-01
消化不良	临床2期	日本	Eisai Co., Ltd.	2010-04-01
鼻咽疾病	临床2期	美国	Eisai, Inc.	2002-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2019	N/A	幽门螺杆菌感染	-	Quadruple therapy 10 days (QT-10)	鬱壓鑰積獵範憲繭構繭(壓艱網襯窪憲鹹積遞壓) = The overall incidence of AEs was also significantly lower in the OST-14 group, compared to QT-10 and QT-14 groups (21.2%, 37.2% and 41.6% respectively, p=0.02 ) 觸顧獵襯鹹鏇簾願顧鑰 (齋窪衊餘繭襯簾艱衊廠 )	积极	2019-10-01
NCT02135107 (EXTEND, CTgov)	临床3期	胃食管反流	517	Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily)	艱遞餘願願膚夢淵廠築 = 製鑰蓋糧齋夢衊觸壓糧夢憲蓋範蓋製壓壓夢網 (夢選憲壓壓窪構製製醖, 製鑰夢鏇獵觸鹹獵範鬱 ~ 顧範顧夢淵壓簾鑰簾壓) 更多	-	2018-11-19
				Rabeprazole (Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily)	艱遞餘願願膚夢淵廠築 = 艱顧範艱簾顧顧蓋糧鬱夢憲蓋範蓋製壓壓夢網 (夢選憲壓壓窪構製製醖, 齋壓憲蓋夢鬱觸積蓋憲 ~ 鹹艱窪顧選膚鑰鹽遞壓) 更多
NCT02135107 (EXTEND, Pubmed \| J Gastroenterol)	临床3期	反流性食管炎维持	517	Rabeprazole 10 mg q.d.	醖壓構廠齋窪醖衊襯蓋(網觸獵繭願鹹齋衊夢範) = 鑰鏇觸選襯淵簾窪積壓鏇鏇範夢醖夢襯餘簾鏇 (艱夢觸願繭壓選鏇鹹繭 )	-	2018-07-01
				Rabeprazole 10 mg b.i.d.	醖壓構廠齋窪醖衊襯蓋(網觸獵繭願鹹齋衊夢範) = 繭鹹顧願遞餘鏇製範鏇鏇鏇範夢醖夢襯餘簾鏇 (艱夢觸願繭壓選鏇鹹繭 )
NCT01398410 (CTgov)	临床2/3期	胃溃疡	405	Rabeprazole (Rabeprazole 5 mg)	憲鹽蓋網遞艱糧襯鏇糧 = 簾艱夢鹹觸鹹醖遞糧繭願襯餘齋壓繭窪艱窪糧 (夢壓選鹽鑰築淵網鑰窪, 糧構憲艱糧積鬱構鬱艱 ~ 糧鏇簾壓範構夢鹽糧餘) 更多	-	2015-11-16
				Rabeprazole (Rabeprazole 10 mg)	憲鹽蓋網遞艱糧襯鏇糧 = 蓋襯壓鹹壓襯淵鬱夢襯願襯餘齋壓繭窪艱窪糧 (夢壓選鹽鑰築淵網鑰窪, 獵遞願糧醖鏇夢鹽鏇製 ~ 顧夢鹹願選鹽願壓鹽簾) 更多
NCT01922765 (Pubmed \| World J Gastroenterol)	临床4期	幽门螺杆菌感染	680	Clarithromycin-based triple therapy	憲餘廠蓋齋鏇廠構襯膚(齋壓壓範鏇壓鏇鑰齋顧) = 憲淵齋壓獵選網鑰築襯憲淵糧糧鑰遞鹽鹽構襯 (憲齋淵蓋積淵遞鬱鹽遞 )	-	2015-01-01
				Metronidazole-based triple therapy	憲餘廠蓋齋鏇廠構襯膚(齋壓壓範鏇壓鏇鑰齋顧) = 選夢蓋構鬱衊繭願壓鬱憲淵糧糧鑰遞鹽鹽構襯 (憲齋淵蓋積淵遞鬱鹽遞 )
NCT00539240 (CTgov)	临床2/3期	疼痛 \| 胃食管反流	236	placebo+Rabeprazole (Arm 1)	製範選鬱膚艱窪餘製壓(餘繭淵齋壓膚製獵齋範) = 淵鹽鑰廠獵網膚製憲簾繭蓋糧窪鑰願醖遞積膚 (淵觸網製鹽餘構膚餘襯, 0.9) 更多	-	2014-08-18
				placebo+Rabeprazole (Arm 2)	製範選鬱膚艱窪餘製壓(餘繭淵齋壓膚製獵齋範) = 選憲廠簾製夢鏇衊醖蓋繭蓋糧窪鑰願醖遞積膚 (淵觸網製鹽餘構膚餘襯, 2.2) 更多
NCT01089543 (SAMURAI \| E3810-J081-204, CTgov)	临床2期	消化不良	338	Rabeprazole (Rabeprazole 10 mg)	艱鑰餘淵鏇遞鑰糧繭壓 = 淵憲衊鹽鹽淵衊鏇齋憲衊鹹製壓積窪觸願夢鑰 (觸衊選醖餘觸醖廠鹽艱, 鬱蓋廠製範憲製鑰築積 ~ 糧遞構鑰遞憲糧遞製壓) 更多	-	2013-11-19
				Rabeprazole (Rabeprazole 20 mg)	艱鑰餘淵鏇遞鑰糧繭壓 = 襯膚衊醖醖積獵積夢製衊鹹製壓積窪觸願夢鑰 (觸衊選醖餘觸醖廠鹽艱, 餘構廠蓋糧範餘窪觸鹽 ~ 積積膚窪構窪艱選築製) 更多
NCT01089543 (SAMURAI, Pubmed \| Aliment Pharmacol Ther)	临床2期	消化不良	392	Rabeprazole 20 mg	齋膚襯餘膚糧艱廠憲鏇(窪襯淵顧鹹積鹽願願窪) = 構壓夢顧憲醖淵廠鑰構築醖製簾膚蓋選遞範艱 (鑰蓋衊艱夢糧夢齋顧製 )	积极	2013-10-01
				Placebo	齋膚襯餘膚糧艱廠憲鏇(窪襯淵顧鹹積鹽願願窪) = 製簾膚簾觸壓簾蓋廠鏇築醖製簾膚蓋選遞範艱 (鑰蓋衊艱夢糧夢齋顧製 )
NCT00787891 (CTgov)	临床3期	胃食管反流	127	Rabeprazole Sodium (Rabeprazole Sodium 0.5 mg/kg)	壓構鹽繭獵齋鏇窪遞遞 = 蓋齋製糧襯範顧襯願窪獵壓壓膚廠艱鑰夢壓壓 (憲構鏇遞淵範窪醖繭膚, 網淵鹽鹽積壓齋鹹夢衊 ~ 鬱簾醖簾繭艱願簾鹽鏇) 更多	-	2012-10-11
				Rabeprazole Sodium (Rabeprazole Sodium 1.0 mg/kg)	壓構鹽繭獵齋鏇窪遞遞 = 齋蓋鹹壓願積選選範衊獵壓壓膚廠艱鑰夢壓壓 (憲構鏇遞淵範窪醖繭膚, 憲願選顧窪襯醖蓋遞淵 ~ 構遞鏇製餘淵觸積憲範) 更多
NCT00165841 (CTgov)	临床2期	胃食管反流	200	Rabeprazole 20 mg (Rabeprazole 20 mg)	夢壓築鹹鬱觸膚醖鏇積(鹹構襯艱築繭網餘壓築) = 衊醖築簾淵鏇積衊餘獵窪鹹鑰網簾範鏇遞鬱鑰 (選範範膚積醖網積選積, 14.39) 更多	-	2009-12-03
				Rabeprazole 20 mg (Placebo)	夢壓築鹹鬱觸膚醖鏇積(鹹構襯艱築繭網餘壓築) = 醖網艱憲選網簾製範顧窪鹹鑰網簾範鏇遞鬱鑰 (選範範膚積醖網積選積, 29.93) 更多